Revised. Amendments from Version 2
==================================

In the current version, we have changed the title, and cited previous research (ref 41 and 54) based on referee suggestions. We have also included some minor corrections as suggested by a co-author.

Introduction
============

Oral glucose elicits a greater insulin response than intravenous glucose infusion, a phenomenon known as the incretin effect ^[@ref-1]^. This effect is mostly attributed to the intestinally derived hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) ^[@ref-2]^. These hormones have a very short half-life as they are rapidly inactivated by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP4) ^[@ref-3]^. The finding that the incretin effect is impaired in subjects with type 2 diabetes ^[@ref-4]^ led to two major types of GLP-1 based therapies ^[@ref-5]^ - intravenously or sub-cutaneously administered GLP-1 mimetics that are resistant to DPP4 (exenatide, liraglutide, etc.) ^[@ref-6]^, and the orally administered gliptins that prolong the physiological actions of incretin hormones by inhibiting DPP4 (sitagliptin, vildagliptin, etc.) ^[@ref-7]--\ [@ref-9]^. Due to the multifarious roles played by the DPP4 enzyme ^[@ref-10]--\ [@ref-12]^, the possible side effects of these drugs (acute pancreatitis, pancreatic cancer, etc. ^[@ref-13]--\ [@ref-15]^) are strongly contested by researchers who argue that current statistics are insufficient ^[@ref-16],\ [@ref-17]^ to conclusively attribute these side effects to the otherwise beneficial GLP-1 drugs ^[@ref-18]^. Compound promiscuity is another phenomenon that might play a crucial role in determining the side effects of these therapies, although this aspect has rarely been pursued intensively ^[@ref-19]^.

Previous work by our group has established the spatial and electrostatic congruence in cognate residue pairs of the active site in proteins with the same functionality (CLASP) ^[@ref-20],\ [@ref-21]^. CLASP analysis indicated that the phosphoinositide-specific phospholipase C (PI-PLC) from *Bacillus cereus* has spatial and electrostatic congruence with a serine protease motif ^[@ref-22]^. This was validated by protease assays, mass spectrometry and by inhibition of the native phospholipase activity of PI-PLC by the well-known serine protease inhibitor AEBSF (IC ~50~ = 0.018 mM). The specificity of the protease activity was for a proline in the amino terminal, suggesting that PI-PLC is a prolyl peptidase, similar to the DPP4 enzyme. This finding led us to believe that the gliptins would have similar inhibitory effect on PI-PLC. In the current work, we have confirmed the inhibition of the native phospholipase activity of PI-PLC using two gliptins - vildagliptin ^[@ref-23]^ (at *µ*-molar concentrations) and K579 ^[@ref-24]^ (at nano-molar concentrations).

Subsequently, we used a motif derived from a DPP4 protein ^[@ref-25]^, in addition to the trypsin motif used previously ^[@ref-22]^, to query a comprehensive and non-redundant (50% sequence identity) list of \~5000 human proteins with known structures using CLASP, intending to identify other proteins that might be inhibited by the gliptins. From the set of proteins with significant congruent matches with these two motifs, we identified a pancreatic lipase ^[@ref-26]^ and a gastric lipase ^[@ref-27]^, keeping the context of lipases, acute pancreatitis and GLP-1 based therapies in mind. Our findings rationalize the elevated levels of serum lipase found in patients undergoing DPP4 inhibitor based therapies ^[@ref-28],\ [@ref-29]^, although these reports are in disagreement with other findings ^[@ref-30],\ [@ref-31]^. While it is logical and expected to find scaffolds that are congruent to trypsin and DPP4 active sites in lipases based on the current results and our previous findings ^[@ref-22]^, we also show the presence of the serine catalytic triad in close proximity to the active site residues of proteins which have a completely different enzymatic mechanism (for example, in glutaminyl cyclase which is a transferase ^[@ref-32]^). This corroborates the current belief that convergent evolution occurs more frequently than previously believed ^[@ref-33]^. Thus, we propose a rational method to identify proteins that might have unintended and undesirable interactions with newly introduced compounds, and substantiate our claims by demonstrating the inhibition of the native phospholipase activity of PI-PLC from *B. cereus* using gliptins that are used in type 2 diabetes therapy.

Results
=======

The active site motifs
----------------------

The active sites of serine proteases differ in their specificities owing to residues other than the conserved catalytic triad. Thus, in addition to the trypsin motif used previously (Asp102, Ser195 and His57 - PDBid 1A0J) ^[@ref-22]^ (Motif1), we choose another motif from a DPP4 enzyme (Asp708, Ser630 and His740 - PDBid:1N1M) (Motif2) ( [Table 1](#T1){ref-type="table"}). Apart from the catalytic triad, we chose another non-polar residue in order to increase the specificity of the matches (Ala56 in Motif1 and Val711 in Motif2). This fourth residue is chosen as the closest residue to any one of the catalytic triad residues. Using the ability of CLASP to include stereochemically equivalent residues, this last residue could be matched by another non-polar residue - one of Gly, Ala, Val, Leu, Ile or Met. Further, it has been seen that the second (ac) and fifth (bd) ( [Table 1](#T1){ref-type="table"}) pairwise electrostatic potential differences (EPD) are not discriminatory - thus, this pair is not used to score the EPD difference (although it is included in the distance deviation score).

###### Potential and spatial congruence of the active site residues in proteins queried using two motifs - Motif1 from Trypsin and Motif2 from DPP4.

Rmsd1 and Rmsd2 are the root mean square deviation of the scaffold with respect to Motif1 and Motif2. DPP4 - dipeptidyl peptidase-IV, PI-PLC - phosphoinositide-specific phospholipase C, PLASE - human pancreatic lipase-Related Protein 2, GPASE - human gastric lipase, QC - glutaminyl cyclase. D = Pairwise distance in Å. PD = Pairwise potential difference. APBS writes out the electrostatic potential in dimensionless units of kT/e where k is Boltzmann's constant, T is the temperature in K and e is the charge of an electron.

  --------------------------------------------------------------------------------------------------------------
  PDB              Active site atoms\        ab       ac      ad       bc      bd       cd       Rmsd1   Rmsd2
                   (a,b,c,d)                                                                             
  ---------------- -------------------- ---- -------- ------- -------- ------- -------- -------- ------- -------
  TRYPSIN (1A0J)   D102,S195\           D\   7.8\     5.6\    2.9\     3.3\    9.0\     6.9\     0       0.5
                   H57,A56              PD   -144.1   -39.2   -248.3   104.8   -104.3   -209.1           

  DPP4 (1N1M)      D708,S630\           D\   7.6\     5.4\    2.6\     2.6\    6.8\     5.4\     0.5     0
                   H740,V711            PD   -154.4   124.4   -148.8   278.8   5.6      -273.2           

  PI-PLC (1PTD)    D67,S234\            D\   8.2\     6.2\    4.1\     3.8\    11.5\    9.2\     0.6     1.1
                   H32,I68              PD   -93.7    39.7    -245.2   133.4   -151.5   -284.8           

  PLASE (2OXE)     D195,S171\           D\   7.7\     6.4\    4.4\     3.0\    6.7\     5.8\     0.5     0.4
                   H282,G235            PD   -150.2   26.7    -132.1   176.9   18.2     -158.8           

  GPASE (1HLG)\    D324,S153,\          D\   7.5\     5.0\    2.9\     2.7\    8.4\     6.2\     0.2     0.3
  Motif1           H353,L326            PD   -202.6   -15.0   -272.3   187.6   -69.7    -257.3           

  GPASE (1HLG)\    D324,S153\           D\   7.5\     5.0\    2.6\     2.7\    7.1\     5.3\     0.4     0.1
  Motif2           H353,A327            PD   -202.6   -15.0   -207.1   187.6   -4.5     -192.1           

  QC (3PB4)        D170,S187,\          D\   7.5\     4.8\    3.4\     3.3\    10.7\    8.0\     0.4     0.8
                   H168,G224            PD   -92.8    -16.5   -214.0   76.3    -121.2   -197.5           
  --------------------------------------------------------------------------------------------------------------

###### Best matches in the set of \~5000 human proteins.

\(a\) Motif1 (Asp102, Ser195, His57, Ala56) from Trypsin (b) Motif2 (Asp708, Ser630, His740, Val711) from DPP4.

  -----------------------------------------------------------------
  Motif   PDB    Description                               CLASP\
                                                           Score
  ------- ------ ----------------------------------------- --------
  1       2ANY   Plasma kallikrein, light chain            0.028

  1       2OQ5   Transmembrane protease, serine 11E        0.037

  1       3U0V   Lysophospholipase-like protein 1          0.041

  1       2ODP   Complement C2                             0.060

  1       1IMJ   CCG1-interacting factor B                 0.065

  1       3F6U   Vitamin K-dependent protein C heavy\      0.065
                 chain                                     

  1       1ELV   Complement C1S component                  0.068

  1       1MD8   C1R complement serine protease            0.068

  1       1ORF   Granzyme A                                0.070

  1       1FJ2   Acyl protein thioesterase 1               0.071

  2       1HLG   Gastric lipase                            0.042

  2       1SPJ   Kallikrein 1                              0.114

  2       2F83   Coagulation factor XI                     0.120

  2       1ZJK   Mannan-binding lectin serine protease 2   0.131

  2       3QLP   Thrombin light chain                      0.145

  2       2QXI   Kallikrein-7                              0.146

  2       2XU7   Histone-binding protein RBBP4             0.174

  2       2W2N   Proprotein convertase subtilisin/kexin\   0.180
                 type 9                                    

  2       2HEH   KIF2C protein                             0.195

  2       2ANY   Plasma kallikrein, light chain            0.197
  -----------------------------------------------------------------

***Inhibition of phosphoinositide-specific phospholipase C (PI-PLC) using dipeptidyl peptidase-IV (DPP4) inhibitors.*** DPP4 (EC 3.4.14.5), a serine protease that is expressed in many tissues (kidney, liver, lung, intestinal membranes, lymphocytes and endothelial cells), cleaves peptides with Pro or Ala residues in the second amino terminal position. Previously, we have experimentally demonstrated the existence of the serine protease domain in PI-PLC from *Bacillus cereus* - both by virtue of its proteolytic activity, and the inhibition of its native activity on phospholipids in the presence of serine protease inhibitors ^[@ref-22]^. Furthermore, the specificity of the proteolytic activity indicated that it was a prolyl peptidase - thus, leading us to believe that DPP4 inhibitors should have a similar inhibitory effect on the PI-PLC enzyme. [Table 1](#T1){ref-type="table"} shows the presence of a congruent motif in the PI-PLC protein with both Motif1 and Motif2. His32 and Asp67 are known to be a part of the active site scaffold in PI-PLC ^[@ref-22]^. These proteins have completely different folds, and thus a superimposition (using both MUSTANG ^[@ref-34]^ and DECAAF ^[@ref-35]^) does not show any detectable similarity in their structures ( [Supplementary Figure 1](#SF1){ref-type="fig"}). [Figure 1](#f1){ref-type="fig"} shows the active sites of these proteins, and the superimposition of these proteins based on their catalytic residues ^[@ref-35]^. It can be seen that the closest non-polar residue to the catalytic triad in trypsin and PI-PLC (Ala56 in PDBid:1A0J, Ile68 in PDBid:1PTD) is differently placed from Val711 in DPP4 (PDBid:1N1M). This is also indicated by the greater RMSD (root mean square deviation) of the scaffold in PI-PLC to Motif2 as compared to Motif1. The differences in the position of peripheral residues is the source of the diverse specificities exhibited by these proteases. [Figure 2](#f2){ref-type="fig"} shows the inhibition of PI-PLC using two gliptins - vildagliptin (LAF-237) ^[@ref-23]^ and K579 ^[@ref-24]^. PI-PLC catalyzes hydrolysis of phospholipids to yield diacylglycerol and a phosphoryl alcohol. In the absence of inhibitors enzyme addition to the vesicle suspension causes an increase in turbidity due to vesicle aggregation ( [Figure 2 a,c](#f2){ref-type="fig"}). Aggregation in turn occurs as a result of formation of the enzyme endproduct diacylglycerol ^[@ref-36],\ [@ref-37]^. A steady-state is reached under our conditions after 6--8 min. Addition of either LAF-237 (vildagliptin) or K579 leads to an obvious inhibition of the enzyme activity. Dose-response curves for the inhibitors are shown in [Figure 2 (b,d)](#f2){ref-type="fig"}. K579 is two orders of magnitude more potent than LAF-237 as a PI-PLC inhibitor, with half-maximal inhibitory concentrations IC ~50~ respectively of 1 *µ*M and 100 *µ*M.

Phosphoinositide-specific phospholipase C inhibition data using the dipeptidyl peptidase-IV inhibitors K-579 and LAF-237Data set for Fig 2 in the main article, describing the inhibition of Phosphoinositide-specific phospholipase C inhibition using the dipeptidyl peptidase-IV inhibitors K-579 and LAF-237.Click here for additional data file.

![The active site residues in Trypsin, DPP4 and PI-PLC.\
( **a**) Trypsin (PDBid:1A0J) ( **b**) DPP4 (PDBid:1N1M); ( **c**) PI-PLC (PDBid:1PTD) ( **d**) Superimposing the active site residues using DE- CAAF ^[@ref-35]^. The superimposition can be viewed in Superimposeproteins.p1m in [Dataset 1](#B1){ref-type="other"}.](f1000research-2-6538-g0000){#f1}

![PI-PLC inhibition using DPP4 inhibitors.\
( **a**, **c**) Time courses of enzyme activity in the presence of varying amounts of inhibitors, respectively LAF-237 and K579. The trace marked LIPOSOMES corresponds to a control in the absence of PI-PLC. ( **b**, **d**) Dose-response effect of inhibitors on PI-PLC activity. Activity was computed as the extent of vesicle aggregation after 10 min enzyme activity.](f1000research-2-6538-g0001){#f2}

***Querying a non-redundant set of human proteins using Motif1 and Motif2.*** Currently, the PDB database has about 25,000 human proteins. Using a identity cutoff of 50%, we chose a set of \~5000 proteins ( [Supplementary Table 1](#ST1){ref-type="table"}) as the target proteins. [Table 2](#T2){ref-type="table"} shows ten proteins which have signicant matches with Motif1 and Motif2. Given the context of lipases, acute pancreatitis and GLP-1 based therapies, we picked two proteins - the human pancreatic lipase-related protein 2 (PDBid:2OXE) ^[@ref-26]^ and a human gastric lipase (PDBid:1HLG) ^[@ref-27]^ - to demonstrate the distinct possibility that these proteins might be inhibited by DPP4 inhibitors. [Table 1](#T1){ref-type="table"} shows the congruence of the DPP4 motif to these proteins using Motif1 and Motif2. It is interesting to note that the gastric lipase (PDBid:1HLG) has a good match with both motifs - Leu326 in PDBid:1HLG is congruent to Ala56 in PDBid:1A0J, and Ala237 (PDBid:1HLG) is congruent to Val711 (PDBid:1N1M).

Since both these proteins are lipases (hydrolases), this congruence to Motif1 and Motif2 is expected based on our previous results with PI-PLC ^[@ref-22]^. However, our methodology also detects other proteins, often with a completely different enzymatic mechanism from hydrolases. A glutaminyl cyclase (PDBid:3PB4 ^[@ref-32]^), a transferase, has a significantly congruent domain with Motif1 (lesser congruence with Motif2, as indicated by the RMSD) ( [Table 1](#T1){ref-type="table"}). [Figure 3](#f3){ref-type="fig"} shows the proximity of the promiscuous scaffold to the active site of the cyclase, and also the congruence of the scaffold to Motif1.

![A scaffold congruent to the active site of Trypsin (PDBid:1A0J) in a glutaminyl cyclase (PDBid:3PB4).\
( **a**) The active site residues are marked in magenta. They are seen to be proximal to the identified scaffold. ( **b**) Superimposition of Motif1 and the scaffold in glutaminyl cyclase. The exact pairwise interatomic distance and electrostatic potential differences are specified in [Table 1](#T1){ref-type="table"}.](f1000research-2-6538-g0002){#f3}

***Docking vildagliptin to the PIPLC structure.*** Since there are no DPP4 structures solved which ligand K-579, a DPP4 protein structure in complex with vildagliptin (PDBid:3W2TA) ^[@ref-38]^ was used to dock vildagliptin to the PIPLC structure complexed with myo-inositol (PDBid:1PTG ^[@ref-39]^) using DOCLASP ^[@ref-40]^ ( [Figure 4](#f4){ref-type="fig"}). The Pymol script for visualizing the docking (SupplementaryPymol.p1m) is provided as [Supplementary information](#sm){ref-type="other"}.

![Docking vildagliptin to the PI-PLC structure in complex with myo-inositol (PDBid:1PTGA).\
Docking done using DOCLASP ^[@ref-40]^. The Pymol script for visualizing the docking (SupplementaryPymol.p1m) is provided as [Supplementary information](#sm){ref-type="other"}.](f1000research-2-6538-g0003){#f4}

***Statistics of atoms making contact with inhibitors.*** There are 76 unique DPP4 inhibitors, defined by three letter codes, for which the ligand-DPP4 structure is solved ( [Supplementary Table 2](#ST2){ref-type="table"}). For uniformity, we chose the first four closest atoms from the protein that make contacts to the ligand, excluding hydrophobic interactions. [Table 3](#T3){ref-type="table"} shows the number of times each residue in DPP4 makes contact to the ligand. Three residues are ubiquitous in making contacts in all these ligands: Glu205, Glu206 and Tyr662 made contacts in 71, 68 and 63 ligands, respectively. Interestingly, Glu205 and Glu206 have been implicated as critical residues for the enzymatic activity of DPP4 through point mutations ^[@ref-41]^. Note, that since only the first four residues were considered, these counts are conservative (and might be more). A recent study has found that inhibitors that bind to residues beyond the extensive subsite (defined as Val207, Ser209, Phe357 and Arg358) increases DPP4 inhibition, as compared to those inhibitors that form a covalent bond with Ser630 ^[@ref-38]^. [Table 3](#T3){ref-type="table"} shows that very few inhibitors make such contacts. We created a library of motifs from these structures that can be used to query any protein using CLASP to determine the possibility that DPP4 inhibitors might bind to it ( [Supplementary Table 3](#ST3){ref-type="table"}), after removing equivalent ones to eliminate redundancy. This table shows the final list of 39 motifs (pruned from the initial 76): this is a comprehensive set of motifs that encapsulates the current knowledge about protein ligand interactions for the DPP4 enzyme. A facet of ligand binding that needs to be accounted for while choosing a motif is the spatial and electrostatic changes that can be induced by ligand binding. Thus, we obtain the residues involved in binding from the holo enzyme, but extract the motif values (pairwise distance and EPD) from the apo enzyme.

###### Number of times residues from the DPP4 enzyme ligand an inhibitor.

Three residues - Glu205, Glu206 and Tyr662 - make contacts in 71, 68 and 63 ligands, respectively. Note, that since we only choose the first four residues based on proximity of the atoms closest to the ligand, these counts are conservative (and might be actually more).

  Residue   Number of ligands
  --------- -------------------
  ARG125    11
  GLU205    71
  GLU206    68
  VAL207    1
  SER209    3
  ARG358    6
  TYR547    18
  GLN553    1
  TYR585    1
  TRP629    1
  SER630    10
  TYR631    12
  TYR662    63
  ASN710    15

Discussion
==========

The controversy regarding the side effects of the dpp4 inhibitors, particularly with respect to acute pancreatitis and pancreatic cancer, continues unabated. While some researchers feel that it is not acceptable to assume that 'absence of evidence is evidence of absence' ^[@ref-42],\ [@ref-43]^, others believe that current data are not conclusive and the 'benefits by far outweigh the potential risks' ^[@ref-16]^. Adding to the uncertainties are conflicting reports presented by different groups ^[@ref-28]--\ [@ref-31]^. Notwithstanding the antagonistic views on the subject, it is unanimously accepted that current data are insufficient to establish a causal pathogenic effect of these drugs on such side effects ^[@ref-44]^.

Various database studies have been undertaken in order to ascertain the effects of the GLP-1 therapies. Some studies 'did not find an association between the use of exenatide or sitagliptin and acute pancreatitis' with the caveat that the 'limitations of this observational claims-based analysis cannot exclude the possibility of an increased risk' ^[@ref-45]^. On the other hand, other studies have shown that the use of 'sitagliptin or exenatide increased the odds ratio for reported pancreatitis 6-fold as compared with other therapies' ^[@ref-14]^. Further, they reported that 'pancreatic cancer was more commonly reported among patients who took sitagliptin or exenatide as compared with other therapies' ^[@ref-14]^. Although these studies concern the usage of both GLP-1 mimetics and the orally administered gliptins, and our study exclusively focusses on gliptins, and is not concerned with the GLP-1 mimetics data. The close relationship between chronic pancreatitis and pancreatic cancer is also a subject of intense research ^[@ref-46]^. Another administrative database study of US adults with type 2 diabetes reported increased odds of hospitalization for acute pancreatitis for patients undergoing GLP-1 based therapies sitagliptin ^[@ref-13]^. Once again, such correlation of GLP-1 based therapies to acute pancreatitis is contested by other studies ^[@ref-47]^.

Our findings rationalize the elevated levels of serum lipase found in patients undergoing DPP4 inhibitor based therapies ^[@ref-28],\ [@ref-29]^, keeping in mind that other studies contradict these reports ^[@ref-30],\ [@ref-31]^. While several studies have reported that the GLP-1 mimetics do not induce pancreatitis in rats, mouse and/or monkey ^[@ref-48]--\ [@ref-50]^, these studies did not include DPP4 inhibitors, which are the compounds that might be responsible for interactions with pancreatic proteins according to our study. It is to be noted however that these mimetics may have other physiological effects and 'the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and merit further investigation' ^[@ref-51]^. Once again, the previous study ^[@ref-51]^ has been challenged by another group who note that 'findings previously reported in rodents may not apply to humans' ^[@ref-52]^.

The orally administered gliptins differ in many aspects such as potency, excretion mechanism, target selectivity, half-life, metabolism and possible drug-drug interactions ^[@ref-9],\ [@ref-53],\ [@ref-54]^. This difference is also highlighted in the different concentrations of vildagliptin and K579 that inhibit PI-PLC. A recent study has also noted the differential off-target inhibition of enzymes by vildagliptin and sitagliptin using a high-throughput, multiplexed assay ^[@ref-55]^. Interestingly, the PI-PLC scaffold has a better match with the trypsin motif than with the DPP4 motif ( [Table 1](#T1){ref-type="table"}). In order to be able to model these differences in our *in silico* search, it is important to be able to provide flexibility in the scoring mechanism.

To summarize, it has been noted in the case of GLP-1 based therapies that as 'evidence of harm accumulates, but is vigorously discounted' the 'burden of proof now rests with those who wish to convince us of their safety' ^[@ref-43]^. Surveillance programs, real-life cohort studies and case-control studies can be supplemented by rational investigations of relevant proteins based on anecdotal reports ^[@ref-56]^. The methodology proposed in the current work, which specifically demonstrates the effects of the DPP4 inhibitors, also presents a rational way of determining the inadvertent interactions of newly designed compounds with proteins, and thus prevent the recurrence of drug induced diseases being detected after considerable damage has already been inflicted on humans subjected to these drugs ^[@ref-57]^.

Materials and methods
=====================

*In silico* analysis
--------------------

A comprehensive, non-redundant set of \~5000 human proteins (50% identity cutoff) was obtained from the PDB database ^[@ref-58]^. The CLASP package ( <http://www.sanchak.com/clasp>) used for querying these proteins using motifs from trypsin and DPP4 is written in Perl on Ubuntu ^[@ref-20]^. Hardware requirements are modest - all results here are from a simple workstation (8GB ram), and runtimes for analyzing the \~5000 proteins was about 24 hours. Adaptive Poisson-Boltzmann Solver (APBS) and PDB2PQR packages were used to calculate the potential difference between the reactive atoms of the corresponding proteins ^[@ref-59],\ [@ref-60]^. The APBS parameters and electrostatic potential units were set as described previously in Chakraborty *et al.* ^[@ref-20]^. All protein structures were rendered by PyMol ( <http://www.pymol.org/>). Protein structures have been superimposed using MUSTANG ^[@ref-34]^ and DECAAF ^[@ref-35]^.

Protein, substrate and reagents
-------------------------------

PI-PLC was purchased from Sigma. Vildagliptin (LAF-237) was obtained from Selleckchem, and K579 was obtained from Santa Cruz.

PI-PLC assay and inhibition using DPP4 inhibitors
-------------------------------------------------

***Vesicle preparation and characterization.*** The appropriate lipids were mixed in organic solution, and the solvent was evaporated to dryness under N ~2~. Solvent traces were removed by evacuating the lipids for at least 2 hours. The lipids were then swollen in 10 mM Hepes, 150 mM NaCl, pH 7.5 buffer. Large unilamellar vesicles (LUV) were prepared from the swollen lipids by extrusion and sized by using 0.1 *µ*m poresize Nuclepore filters, as described by Ahyayauch *et al.* ^[@ref-36]^. LUV composition was egg phosphatidylcholine: egg phosphatidylethanolamine: cholesterol at a 2:1:1 mole ratio. The average size of LUV was measured by quasi-elastic light scattering, using a Malvern Zeta-sizer instrument. Lipid concentration, determined by phosphate analysis, was 0.3 mM in all experiments.

***Aggregation Assay.*** Enzyme activity was assayed measuring enzyme-induced vesicle aggregation. All assays were carried out at 39°C with continuous stirring, in 10 mM Hepes, 150 mM NaCl buffer (pH 7.5), in the presence of 0.1% BSA for optimum catalytic activity. Enzyme concentration was 0.16 U/mL, and liposomal concentration was 0.3 mM. Lipid aggregation was monitored in a Cary Varian UV-vesicle spectrometer as an increase in turbidity (absorbance at 450 nm) of the sample, as described by Villar *et al.* ^[@ref-37]^. The data are average values of two closely similar experiments.

***Analyzing known DPP4 inhibitors with solved structures.*** In order to obtain all known structures of DPP4 with inhibitors bound to the active site, we did a search for the keyword dipeptidyl-peptidase on the PDB database, and choose proteins with DPP4 inhibitors as ligands. There are 76 such unique compounds (defined by three letter codes) that are reported to date (May 2014). We docked the DPP4 inhibitor to the PIPLC active site using DOCLASP ^[@ref-40]^.

Data availability
=================

figshare: Phosphoinositide-specific phospholipase C inhibition data using the dipeptidyl peptidase-IV inhibitors K-579 and LAF-237, <http://dx.doi.org/10.6084/m9.figshare.880620>

We are grateful to Jean-Marie Frère, Centre for Protein Engineering, Universite de Liège, Institut de Chimie B6, Sart Tilman, B-4000 Liège, Belgium for critical inputs.

Supplementary information {#sm}
=========================

Supplementary Pymol scripts. Click here to access the files. <http://dx.doi.org/10.5256/f1000research.3002.s40929>

![Superimposition of trypsin (PDBid:1A0J - magenta), dipeptidyl peptidase-IV (PDBid:1N1M - yellow) and phosphoinositide-specific phospholipase C (PDBid:1PTD - cyan).\
It is seen that there is no structural similarity in the two proteins. ( **a**) Using MUSTANG ^[@ref-34]^. ( **b**) Using DECAAF ^[@ref-35]^.](f1000research-2-6538-g0004){#SF1}

###### PDB IDs of ∼5000 human proteins analyzed in this study.

  -------------------------------------------------------------------------------------------------
  1A02 1A12 1A17 1A1W 1A1X 1A27 1A31 1A35 1A36 1A3Q 1A4I 1A66 1A6Q 1A6Y 1A7S 1A9N 1AAP\
  1AB2 1AD6 1ADX 1ADZ 1AIE 1AJJ 1ALE 1ALF 1ALU 1ALY 1AM9 1AN4 1AOA 1APJ 1APQ 1APY\
  1AQC 1ATZ 1AU1 1AUD 1AV1 1AVO 1AW0 1AWE 1AWW 1AX8 1AYE 1B1C 1B22 1B34 1B4F 1B4G\
  1B4Q 1B4R 1B64 1B6A 1B6E 1B6U 1B72 1B9O 1BA5 1BAK 1BBO 1BC7 1BC8 1BCI 1BD8 1BF5 1BH7\
  1BH9 1BHD 1BHI 1BIK 1BJ8 1BKR 1BL1 1BNK 1BNL 1BO9 1BOE 1BOR 1BPV 1BPX 1BPY 1BPZ\
  1BQU 1BTK 1BTR 1BTS 1BUO 1BV8 1BW6 1BX4 1BY1 1BY2 1BY4 1BYG 1BYW 1BZ4 1BZG 1C07\
  1C7U 1C9B 1CB0 1CCZ 1CDW 1CF7 1CI4 1CJY 1CK7 1CKS 1CMZ 1CNT 1CQ0 1CQT 1CR8 1CS8\
  1CSK 1CSY 1CVJ 1CXW 1CY5 1CZA 1CZT 1CZY 1D2J 1D2L 1D2S 1D3B 1D4A 1D4B 1D4T 1D4U\
  1D5R 1D7Q 1D8J 1D9N 1DBH 1DD1 1DDJ 1DE8 1DE9 1DEB 1DEU 1DEW 1DG6 1DGF 1DGN 1DHS\
  1DJL 1DK8 1DLE 1DN3 1DNG 1DNU 1DQB 1DSZ 1DT9 1DTJ 1DUX 1DV0 1DV8 1DXS 1DXX 1DYN\
  1DZ5 1E07 1E17 1E2S 1E3O 1E4U 1E7K 1E88 1E8O 1E8S 1E8Y 1E9K 1EAJ 1EAZ 1EBM 1EC6 1EDM\
  1EDN 1EDP 1EER 1EF7 1EFV 1EG3 1EGD 1EGI 1EGT 1EGW 1EH6 1EIG 1EJ9 1EJF 1EK6 1ELK\
  1ELR 1ELV 1ELW 1EM2 1EMH 1EMJ 1EMN 1EMU 1EQX 1ET1 1ETE 1EVS 1EWF 1EWN 1EX0 1EXT\
  1EXZ 1EYB 1F05 1F0Y 1F2L 1F2Q 1F3U 1F4R 1F5N 1F5Y 1F62 1F6O 1F6W 1F7E 1F86 1F9P 1FAC\
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  3SNV 3SOA 3SOC 3SOE 3SOM 3SOO 3SOV 3SP7 3SP8 3SPA 3SQD 3SR4 3SSU 3SW0 3SWK 3SWR\
  3SWY 3SWZ 3SYX 3SZA 3SZR 3T0H 3T0O 3T1I 3T1W 3T30 3T3L 3T5O 3T5X 3T6A 3T6P 3T7A 3T7L\
  3T92 3TBD 3TBG 3TC5 3TDC 3TDU 3TE3 3TEG 3TEQ 3TFR 3TFS 3TG4 3TGX 3THC 3THT 3THW\
  3THX 3THY 3THZ 3TIW 3TJM 3TJO 3TJQ 3TKU 3TKZ 3TLP 3TMI 3TMM 3TN2 3TNU 3TO8 3TOJ\
  3TOP 3TOW 3TQ1 3TQ6 3TRT 3TS8 3TSV 3TSZ 3TT0 3TT9 3TTJ 3TUO 3TV0 3TWR 3TYY 3TZD\
  3TZM 3U0R 3U0V 3U10 3U12 3U1K 3U1N 3U1U 3U21 3U23 3U2P 3U2U 3U3P 3U3Z 3U5L 3U5S 3U83\
  3U8I 3U9H 3U9J 3U9Q 3U9W 3UB2 3UBY 3UCG 3UCU 3UCW 3UCZ 3UD1 3UD3 3UD4 3UE2 3UEM\
  3UF1 3UFJ 3UFN 3UGC 3UI4 3UK3 3UKM 3ULH 3ULL 3UMH 3UN9 3UNN 3UO7 3UO9 3UOA 3UOB\
  3UOM 3UP1 3UPQ 3UQ0 3UQ2 3URF 3URO 3US0 3US1 3US2 3UUN 3UV2 3UV4 3UV5 3UVT 3UW5\
  3UWT 3UX2 3V2A 3V2B 3V30 3V33 3V34 3V3E 3V3L 3V42 3V43 3V4K 3V4O 3V4Q 3V53 3V56 3V70\
  3V79 3V8D 3V8S 3V98 3V9H 3VAF 3VAG 3VAH 3VAI 3VAJ 3VAL 3VAM 3VBB 3VD0 3VD1 3VD2 3VF3\
  3VFD 3VG7 3VHE 3VHS 3VHV 3VI6 3VJ9 3VKE 3VN9 3VNN 3VO3 3VOQ 3VOW 3VOY 3VPP 3VTU\
  3VTV 3VTW 3VVV 3VW9 3VYX 3VYY 3VZB 3W1B 3W3J 3W9Y 3ZCW 3ZD2 3ZDK 3ZI1 3ZIM 3ZJC\
  3ZJE 3ZN0 3ZNF 3ZNN 3ZNV 3ZON 3ZQK 3ZQS 3ZR0 3ZRH 3ZRT 3ZSJ 3ZTG 3ZVZ 3ZW5 3ZWF\
  3ZWT 3ZXF 3ZY0 3ZYQ 3ZYW 4A04 4A0D 4A0P 4A14 4A1G 4A1N 4A24 4A27 4A35 4A3N 4A3P 4A4F\
  4A4I 4A5S 4A5X 4A5Z 4A64 4A6D 4A7U 4A82 4A9C 4A9Z 4AA6 4AAA 4ABL 4ABM 4ACQ 4ACR 4AD9\
  4AE2 4AE7 4AE8 4AFL 4AGU 4AH6 4AIF 4AIW 4AJ5 4AJY 4AK8 4AKM 4AKV 4AL0 4ALG 4AMT\
  4ANK 4AOH 4AOW 4AP5 4AP8 4APO 4AQB 4AQL 4AS4 4ASC 4ASZ 4ATM 4AUV 4AVP 4AVS 4AW0\
  4AW6 4AWL 4AWN 4AY2 4AYA 4AYT 4AZ3 4AZ9 4B0F 4B2R 4B2S 4B3F 4B3G 4B4C 4B4O 4B53 4B5O\
  4B6D 4B6H 4B7L 4B7Y 4B87 4B91 4B94 4B9D 4BB9 4BBQ 4BC3 4BD2 4BDV 4BDX 4BEJ 4BGJ 4BGQ\
  4BHX 4BK0 4BKJ 4BKW 4BL1 4BN4 4BPB 4BQA 4BQY 4BSP 4D86 4D8K 4D8O 4D90 4DA1 4DA5\
  4DB1 4DBG 4DD8 4DDJ 4DDP 4DEQ 4DGJ 4DHX 4DIP 4DJC 4DK9 4DKC 4DKK 4DKX 4DL2 4DL3\
  4DL4 4DL5 4DL6 4DL7 4DLO 4DND 4DNL 4DO4 4DO9 4DOA 4DOB 4DOC 4DOH 4DON 4DOU 4DPZ\
  4DQY 4DRI 4DUR 4DVQ 4DWF 4DXT 4DY0 4DYL 4DYO 4DZO 4E1H 4E1I 4E1O 4E34 4E45 4E4H\
  4E54 4E5Y 4E5Z 4E6R 4E74 4E82 4E9E 4E9F 4E9G 4E9M 4EA4 4EA5 4EAR 4EBB 4EBC 4EBD 4EBE\
  4ECQ 4ECR 4ECS 4ECT 4ECU 4ECV 4ECW 4ECX 4ECY 4ECZ 4ED0 4ED1 4ED2 4ED3 4ED5 4ED6\
  4ED7 4ED8 4EEW 4EEY 4EF0 4EFO 4EGL 4EGX 4EHD 4EI1 4EI3 4EIH 4EJN 4EJQ 4EKU 4EKZ 4ELJ\
  4ELL 4EMO 4EMT 4ENZ 4EO7 4EOT 4EOZ 4EPU 4ERC 4ERN 4ERV 4ERY 4ES7 4ESR 4EUT 4EUU\
  4EUW 4EWE 4EWI 4EYH 4EYI 4EZF 4F02 4F0D 4F11 4F14 4F25 4F2J 4F3J 4F3T 4F6M 4F6N 4F6U\
  4F7H 4F7O 4F80 4F92 4F9C 4F9K 4F9Z 4FBN 4FC7 4FCJ 4FDI 4FGL 4FH0 4FHQ 4FIE 4FKA 4FKL\
  4FL3 4FLA 4FLB 4FMU 4FMW 4FNC 4FO0 4FO6 4FO9 4FOM 4FQG 4FQN 4FQP 4FR4 4FRW 4FTG\
  4FU3 4FU6 4FVQ 4FWW 4FXM 4FXV 4FXW 4FYO 4FYT 4FZV 4G0F 4G1M 4G1T 4G31 4G3O 4G82\
  4G83 4G84 4G85 4G8K 4G9A 4GA0 4GA7 4GBA 4GDK 4GDV 4GE6 4GEH 4GEI 4GGA 4GGC 4GGF\
  4GIF 4GIW 4GJZ 4GL2 4GLM 4GLP 4GMJ 4GMV 4GNE 4GO6 4GOF 4GOS 4GQ4 4GQB 4GQR 4GRZ\
  4GS4 4GT4 4GUT 4GV1 4GV2 4GWG 4GWM 4GXL 4GYW 4GYX 4H10 4H22 4H27 4H2D 4H2G 4H6Y\
  4H75 4H7W 4H7Y 4H87 4H9N 4HAE 4HAN 4HAS 4HBD 4HBQ 4HC4 4HC7 4HC9 4HCA 4HCK 4HCU\
  4HCZ 4HFX 4HL4 4HLH 4HOQ 4HOR 4HOS 4HOT 4HOU 4HPF 4HPM 4HQA 4HQU 4HQX 4HR9 4HRG\
  4HT2 4HTJ 4HTM 4HTP 4HVC 4HW4 4HWK 4HWN 4HXH 4HY4 4HZH 4HZR 4HZS 4I1F 4I4E 4I5I 4I5J\
  4I6O 4I6X 4I79 4IAX 4IC3 4IC7 4IDO 4IDT 4IE5 4IEJ 4IF8 4IG8 4IGD 4IGG 4IGZ 4II1 4IIM 4IJD 4IJX\
  4IKD 4IKP 4IM0 4IN0 4INC 4IQR 4IQY 4IR5 4IS1 4ITJ 4IU6 4IUL 4IVE 4IYP 4J0W 4J15 4J19 4J1Y\
  4J37 4J3M 4J5R 4J6G 4J8S 4J9K 4J9L 4J9M 4J9N 4J9O 4J9P 4J9Q 4J9R 4J9S 4JA8 4JGC 4JGT 4JHN\
  4JHS 4JIF 4JJ7 4JJH 4JK8 4JNC 4JNK 4JOI 4JOL 4JON 4JQF 4JSN 4JUY 4JV8 4JVH 4JWM 4JWN\
  4JXO 4K6J 4K92 4KA4 4KBL 4KFO 4KM5 4KNV 4KRF 4KSY 4KT1 4L0N 4L58 4L6E 4SKN 5ZNF 6PAX\
  6RLX 7ICE 7ICF 7ICG 7ICH 7ICI 7ICJ 7ICK 7ICL 7ICM 7ICN 7ICO 7ICP 7ICQ 7ICR 7ICS 7ICT 7ICU\
  7ICV 8ICA 8ICB 8ICC 8ICE 8ICF 8ICG 8ICH 8ICI 8ICJ 8ICK 8ICL 8ICM 8ICN 8ICO 8ICP 8ICQ 8ICR\
  8ICS 8ICT 8ICU 8ICV 8ICW 8ICX 8ICY 8ICZ 9ICA 9ICB 9ICC 9ICE 9ICF 9ICG 9ICH 9ICI 9ICJ 9ICK\
  9ICL 9ICM 9ICN 9ICO 9ICP 9ICQ 9ICR 9ICS 9ICT 9ICU 9ICV 9ICW 9ICX 9ICY

  -------------------------------------------------------------------------------------------------

###### Residues of DPP4 closest to the bound ligand with possible hydrogen bonds.

Interactions sorted based on the distance. N: Number of atoms in the ligand, R/A/LA/D: Residue number/Atom of the residue/Atom of ligand/distance between the interacting atoms (in Å). For example, 'E205/OE1/N25/2.7' means that the atom OE1 from Glu205 is at 2.7 Å from the N25 atom of W94 in PDBid:3VJLA. For uniformity, we choose the first four closest atoms. This might result in choosing some atoms which are unlikely to form a hydrogen bond (for example, in PDBid:4J3JA S209/OG is at 4.8 Å from NAQ).

  PDB     HET   N    R/A/LA/D           R/A/LA/D           R/A/LA/D            R/A/LA/D
  ------- ----- ---- ------------------ ------------------ ------------------- ------------------
  3VJLA   W94   33   E205/OE1/N25/2.7   E206/OE1/N25/2.8   N710/ND2/O33/2.9    Y662/OH/O33/3
  2AJ8A   SC3   26   E205/OE2/N13/2.7   E206/OE1/N13/3     Y631/N/O23/3.1      Y547/OH/N7/3.4
  2RGUA   356   35   E205/OE2/N27/3     Y662/OH/N27/3.1    Y631/N/O10/3.1      E206/OE2/N27/3.1
  4A5SA   N7F   37   E205/OE2/N18/2.7   E206/OE2/N18/2.7   Y662/OH/N18/2.8     Y631/N/O26/3
  2QTBA   474   32   E205/OE2/N6/2.7    N710/ND2/O7/2.8    E206/OE1/N6/2.8     R358/NE/N56/2.8
  2OGZA   U1N   24   Y631/N/O25/3       E206/OE1/N12/3.1   R125/NH2/O15/3.1    E205/OE2/O15/3.3
  2JIDA   GVB   24   E206/OE2/N20/2.8   E205/OE2/N20/2.9   Y662/OH/N20/3       R125/NH1/O25/3.8
  2I78B   KIQ   31   Y662/OH/N/3        E205/O/O/4.1       E206/OE1/O/4.2      R669/NH2/O/4.4
  3H0CA   PS4   32   E205/OE2/N21/2.7   Y662/OH/N21/2.9    E206/OE2/N21/2.9    Q553/N/O3/3
  2AJLI   JNH   24   S630/OG/N3/2.3     E206/OE2/N2/2.5    Y547/OH/N3/2.6      E205/OE2/N2/2.7
  2BUBA   FPB   28   E206/OE2/N18/2.5   E205/OE2/N18/2.9   Y662/OH/N18/3       Y547/OH/O16/4.3
  4DSAA   D1C   29   E206/OE2/NAY/2.6   E205/O/OBC/3.1     Y662/OH/NAY/3.1     Y585/OH/NAI/3.9
  2OPHA   277   23   E205/OE2/N33/2.7   N710/ND2/O32/2.8   Y662/OH/N33/3.1     E206/OE2/N33/3.1
  1RWQA   5AP   27   Y662/OH/N21/2.5    E206/OE2/N21/2.8   E205/OE2/N23/2.9    R125/NH2/N1/3.4
  2QJRA   PZF   29   E205/OE2/N20/2.6   R358/NE/O18/2.8    E206/OE2/N20/2.9    Y662/OH/N20/3
  2FJPA   S14   31   E205/OE2/N30/2.7   N710/ND2/O32/2.8   E206/OE2/N30/2.8    Y547/OH/O33/2.8
  2OAEA   AIL   21   E203/OE2/N2/2.8    E204/OE2/N2/2.8    N711/ND2/O8/3.1     Y663/OH/N9/3.1
  3G0CA   RUF   27   E205/OE1/N9/3      E206/OE1/N9/3.2    Y631/N/O23/3.4      Y547/OH/N12/3.6
  3C43A   315   31   E205/OE2/N6/2.8    Y662/OH/N6/3       N710/ND2/O5/3       E206/OE2/N6/3
  3BJMA   BJM   23   S630/OG/N23/2.4    E205/OE2/N7/2.7    E206/OE2/N7/2.7     Y547/OH/O15/2.8
  3O95A   01T   26   E206/OE2/N13/2.5   E205/OE1/N13/2.8   Y662/OH/N13/2.8     R125/NH1/O19/3
  3G0GA   RUM   24   E205/OE1/N24/2.9   E206/OE1/N24/3.1   Y631/N/O8/3.2       R125/NH2/N17/3.3
  2G5PA   ADF   29   S630/OG/N22/2.4    Y662/OH/N8/3.1     Y547/OH/N22/3.1     E206/OE2/N7/3.1
  2BUCA   008   26   E206/OE2/N10/2.7   Y662/OH/N10/2.8    E205/OE2/N10/3      Y547/OH/O13/4.5
  2QOEA   448   29   E206/OE2/N20/2.7   E205/OE2/N20/2.9   Y662/OH/N20/2.9     Y547/OH/O22/4.6
  2OLEA   KR2   30   E206/OE2/NAM/2.7   Y662/OH/NAM/3.6    E205/OE2/NAM/4      Y547/OH/OAP/4.5
  3KWFA   B1Q   27   E205/OE2/N21/2.7   N710/ND2/O19/2.7   Y662/OH/N21/3       R125/NH2/O19/3
  3SX4A   KXA   58   Y662/OH/N25/2.7    E206/OE2/N25/2.7   E205/OE2/N25/2.8    R125/NH1/O26/3.1
  2ONCA   SY1   27   E205/OE1/N1/2.6    Y631/N/O17/3.1     Y547/OH/N18/3.2     E206/OE1/N1/3.4
  2I03B   AXD   29   S630/OG/N14/2.4    E206/OE1/N1/2.8    Y662/OH/O16/2.9     Y547/OH/N14/3
  3KWJA   23Q   27   E205/OE2/N17/2.6   Y662/OH/N17/2.8    E206/OE2/N17/2.8    S209/OG/O19/3.3
  3CCCA   7AC   21   E205/OE1/N20/2.5   Y662/OH/N20/2.7    E206/OE2/N20/3.2    Y631/N/N9/3.3
  3SWWA   KXB   25   E205/OE2/N21/2.7   Y662/OH/N21/2.8    E206/OE2/N21/2.9    R125/NH2/N19/3.5
  4G1FA   0WG   24   E206/OE2/N9/2.8    Y662/OH/N9/2.9     Y547/OH/N2/3.1      Y631/N/O20/3.1
  3C45A   317   30   E205/OE2/N6/2.8    E206/OE2/N6/2.8    Y662/OH/N6/3        Y547/OH/N29/3.7
  2G63B   AAF   29   S630/OG/N18/2.4    E205/OE2/N7/2.6    Y662/OH/N8/3.1      Y547/OH/N18/3.1
  1X70A   715   28   E206/OE2/N20/2.7   E205/OE2/N20/2.8   Y662/OH/N20/2.8     S209/OG/N27/3.9
  2GBIA   XIH   29   E204/OE2/N14/2.3   Y632/N/O/2.8       E203/OE2/N14/3      Y663/OH/N14/3.1
  3G0BA   T22   25   E205/OE1/N13/2.5   R125/NH2/N24/3.1   Y631/N/O26/3.2      E206/OE1/N13/3.3
  2IITA   872   28   E205/OE2/N20/2.7   Y662/OH/N20/2.8    E206/OE2/N20/2.9    N710/OD1/N20/4.5
  4JH0A   1MD   27   Y662/OH/N16/2.7    E206/OE2/N16/2.7   Y547/OH/O1/2.8      E205/OE2/N16/2.9
  4LKOA   1WH   25   Y662/OH/N/2.7      E206/OE2/N/2.8     E205/OE2/N/2.9      Y547/OH/O2/3
  2RIPA   34Q   25   N710/ND2/O1/2.6    E205/OE2/N3/2.8    Y662/OH/N3/2.8      E206/OE1/N3/2.8
  3QBJA   NXZ   25   Y662/OH/N18/2.7    E206/OE2/N18/2.7   N710/ND2/O25/2.8    E205/OE2/N18/2.9
  3HACA   361   23   Y662/OH/N23/2.7    E205/OE2/N23/2.8   E206/OE1/N12/4.2    N710/OD1/N23/4.3
  3VJMA   W61   32   E205/OE1/N28/2.7   E206/OE1/N28/2.7   Y662/OH/O57/2.9     N710/ND2/O57/2.9
  3O9VA   10T   23   Y547/OH/O15/2.5    E206/OE2/N19/2.6   Y662/OH/N19/2.7     E205/OE1/N19/2.8
  4DSZA   DC3   26   E206/OE2/NAM/2.8   E205/OE2/NAM/3.1   Y662/OH/NAM/3.1     S209/OG/NAR/4.7
  4J3JA   D3C   30   E206/OE2/NAM/2.8   E205/OE2/NAM/3.1   Y662/OH/NAM/3.3     S209/OG/NAQ/4.8
  4DTCA   D5C   33   E206/OE2/NAM/2.7   E205/OE2/NAM/3.1   Y662/OH/NAM/3.3     R669/NH2/OAQ/4.2
  3OPMA   LUI   28   E205/OE1/N18/2.7   Y662/OH/N18/2.8    E206/OE2/N18/2.9    W629/O/N27/3
  2OAGB   DLI   31   E205/OE2/N22/2.5   Y662/OH/N22/2.6    E206/OE2/N22/2.9    R358/NE/O1/3.2
  2GBGA   1AD   19   S631/OG/N12/2.4    E203/OE2/N14/2.7   Y548/OH/N12/3       E204/OE2/N14/3.1
  2HHAA   3TP   26   E205/OE2/N6/2.7    E206/OE2/N6/2.7    Y662/OH/N6/2.9      N710/ND2/O5/2.9
  2QT9A   524   31   E205/OE2/N19/2.6   E206/OE2/N19/2.8   Y662/OH/N19/2.9     N710/ND2/O20/2.9
  2OQVA   MA9   32   E206/OE2/N27/2.7   Y662/OH/N27/3      R358/NE/O4/3.1      E205/OE2/N27/3.3
  3F8SA   PF2   26   E205/OE2/N3/2.5    Y662/OH/O7/2.8     N710/OD1/O7/3       E206/OE2/N3/3.2
  2AJBA   0QG   24   S630/OG/N2/2.4     E205/OE2/N/2.7     HIS740/NE2/O2/2.9   Y662/OH/O/3
  2G5TA   ACF   26   S630/OG/N22/2.4    E205/OE2/N7/2.6    Y662/OH/O3/3        N710/ND2/O3/3
  3NOXA   6A5   28   E205/OE2/N16/2.4   E206/OE2/N16/2.7   Y662/OH/N16/3       R125/NH2/N4/3.7
  3W2TA   LF7   22   S630/OG/N2/2.4     E205/OE1/N12/2.8   Y662/OH/O20/3       E206/OE2/N12/3
  3D4LA   605   26   E205/OE2/N15/2.6   R358/NE/O42/2.8    Y662/OH/N15/2.9     V207/O/N41/2.9
  2QKYA   13Z   26   S630/OG/O2/2.1     E205/O/O4/2.5      Y547/OH/O2/2.6      E206/OE1/O4/2.8
  3Q8WA   AZV   38   R125/NH1/O/2.5     E206/OE2/NAG/2.6   Y662/OH/NAG/2.8     E205/OE2/NAG/2.9
  3EIOA   AJH   33   Y585/OH/OBD/2.6    E205/OE2/NBG/2.7   Y662/OH/NBG/2.9     E206/OE2/NBG/2.9
  3Q0TA   LGE   26   Y662/OH/N21/2.6    E205/OE2/N21/2.7   E206/OE2/N21/2.9    R125/NH1/O22/3.4
  2P8SA   417   58   E205/OE2/N38/2.8   E206/OE2/N38/2.9   Y662/OH/N38/3.2     S209/OG/N34/3.4
  2OQIB   GGO   28   E205/OE2/N/2.4     Y662/OH/N/2.7      E206/OE2/N/2.9      R358/NE/O/3.2
  4PNZA   2VH   28   E205/OE2/N/2.7     E206/OE2/N/2.8     Y662/OH/N/2.9       Y547/OH/O/3.2
  3VJKA   M51   30   E205/OE1/N21/2.9   Y662/OH/O30/2.9    E206/OE1/N21/2.9    N710/ND2/O30/3
  3OC0A   B2Q   23   E205/OE2/NS/2.8    S209/OG/OB/2.9     Y662/OH/NS/3.4      E206/OE2/NS/3.5
  4N8DA   2KS   24   E206/OE2/N10/2.7   E205/OE2/N10/2.8   Y662/OH/N10/2.8     N710/OD1/N10/4.5
  4N8EA   2KV   22   E205/OE2/N15/2.7   E206/OE2/N15/2.7   Y662/OH/N15/2.8     N710/OD1/N15/4.3
  2IIVA   565   24   E205/OE2/N20/2.7   Y662/OH/N20/2.8    E206/OE2/N20/2.9    N710/ND2/N20/4.4
  3HABA   677   27   E205/OE2/N23/2.7   Y662/OH/N23/2.7    E206/OE1/N12/4.3    N710/OD1/N23/4.4
  2I3ZA   LIR   27   E203/OE2/N18/2.5   Y632/N/O9/2.7      Y548/OH/N6/3.4      E204/OE2/N18/3.4

###### Library of non-redundant motifs.

This library of motifs can be used to query any protein using CLASP to determine the possibility that DPP4 inhibitors might bind to it.

  PDB     Motif Name   Motif
  ------- ------------ --------------------------------------------
  3VJLA   2OQVA1       GLU205/OE1 GLU206/OE1 TYR662/OH ASN710/ND2
  2AJ8A   2OQVA2       GLU205/OE2 GLU206/OE1 TYR547/OH TYR631/N
  2RGUA   2OQVA3       GLU205/OE2 GLU206/OE2 TYR631/N TYR662/OH
  2QTBA   2OQVA4       GLU205/OE2 GLU206/OE1 ARG358/NE ASN710/ND2
  2OGZA   2OQVA5       ARG125/NH2 GLU205/OE2 GLU206/OE1 TYR631/N
  2JIDA   2OQVA6       ARG125/NH1 GLU205/OE2 GLU206/OE2 TYR662/OH
  2I78B   2OQVA7       GLU205/O GLU206/OE1 TYR662/OH ARG669/NH2
  3H0CA   2OQVA8       GLU205/OE2 GLU206/OE2 GLN553/N TYR662/OH
  2AJLI   2OQVA9       GLU205/OE2 GLU206/OE2 TYR547/OH SER630/OG
  2BUBA   2OQVA10      GLU205/OE2 GLU206/OE2 TYR547/OH TYR662/OH
  4DSAA   2OQVA11      GLU205/O GLU206/OE2 TYR585/OH TYR662/OH
  2OPHA   2OQVA12      GLU205/OE2 GLU206/OE2 TYR662/OH ASN710/ND2
  1RWQA   2OQVA13      ARG125/NH2 GLU205/OE2 GLU206/OE2 TYR662/OH
  2QJRA   2OQVA14      GLU205/OE2 GLU206/OE2 ARG358/NE TYR662/OH
  2FJPA   2OQVA15      GLU205/OE2 GLU206/OE2 TYR547/OH ASN710/ND2
  2OAEA   2OQVA16      GLU205/OE2 GLU206/OE2 TYR662/OH ASN711/ND2
  3G0CA   2OQVA17      GLU205/OE1 GLU206/OE1 TYR547/OH TYR631/N
  3O95A   2OQVA18      ARG125/NH1 GLU205/OE1 GLU206/OE2 TYR662/OH
  3G0GA   2OQVA19      ARG125/NH2 GLU205/OE1 GLU206/OE1 TYR631/N
  2G5PA   2OQVA20      GLU206/OE2 TYR547/OH SER630/OG TYR662/OH
  3KWFA   2OQVA21      ARG125/NH2 GLU205/OE2 TYR662/OH ASN710/ND2
  2I03B   2OQVA22      GLU206/OE1 TYR547/OH SER630/OG TYR662/OH
  3KWJA   2OQVA23      GLU205/OE2 GLU206/OE2 SER209/OG TYR662/OH
  3CCCA   2OQVA24      GLU205/OE1 GLU206/OE2 TYR631/N TYR662/OH
  4G1FA   2OQVA25      GLU206/OE2 TYR547/OH TYR631/N TYR662/OH
  2G63B   2OQVA26      GLU205/OE2 TYR547/OH SER630/OG TYR662/OH
  2IITA   2OQVA27      GLU205/OE2 GLU206/OE2 TYR662/OH ASN710/OD1
  2RIPA   2OQVA28      GLU205/OE2 GLU206/OE1 TYR662/OH ASN710/ND2
  3HACA   2OQVA29      GLU205/OE2 GLU206/OE1 TYR662/OH ASN710/OD1
  3O9VA   2OQVA30      GLU205/OE1 GLU206/OE2 TYR547/OH TYR662/OH
  4DTCA   2OQVA31      GLU205/OE2 GLU206/OE2 TYR662/OH ARG669/NH2
  3OPMA   2OQVA32      GLU205/OE1 GLU206/OE2 TRP629/O TYR662/OH
  2AJBA   2OQVA33      GLU205/OE2 SER630/OG TYR662/OH HIS740/NE2
  2G5TA   2OQVA34      GLU205/OE2 SER630/OG TYR662/OH ASN710/ND2
  3W2TA   2OQVA35      GLU205/OE1 GLU206/OE2 SER630/OG TYR662/OH
  3D4LA   2OQVA36      GLU205/OE2 VAL207/O ARG358/NE TYR662/OH
  2QKYA   2OQVA37      GLU205/O GLU206/OE1 TYR547/OH SER630/OG
  3EIOA   2OQVA38      GLU205/OE2 GLU206/OE2 TYR585/OH TYR662/OH
  2I3ZA   2OQVA39      GLU205/OE2 GLU206/OE2 TYR547/OH TYR631/N
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Thank you to the authors for developing this paper.

I have some further comments.

  The primary issue now is the speculation in the title.The title seeks to extrapolate the obtained data on two compounds to suggest that it is applicable to all DPP-IV inhibitors.That is, the speculation of this paper is that the presented data is relevant to an entire drug class. The comments and the title should be restricted to one or two of the compounds that were studied in this paper. Moreover, K-579 is not a diabetes drug. In this context, the title needs changing to avoid ambiguity.I suggest:"The dipeptidyl peptidase IV inhibitor vildagliptin used in type 2 diabetes inhibits a phospholipase C: a case of promiscuous scaffolds in proteins."or"The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins."This study complements the much broader work using focused, direct technology for measuring and detecting off-target inhibition. That paper is published in Nature Chemical Biology in 2014 ( [Bachovchin *et al.* 2014](http://www.ncbi.nlm.nih.gov/pubmed/24997602)). That study similarly showed that vildagliptin inhibits enzymes other than DPP-IV. That study showed that DPP4 inhibitors differ, such that sitagliptin does not inhibit other enzymes.The authors need to comment and restrict their conclusions to the compounds that they studied rather than imply that DPP-IV inhibiting compounds that they did not study, such as sitagliptin, have similar characteristics to the compounds that they did study.The data of this study is biochemical yet 16 of the cited references concern the safety of DPP-IV inhibition. The manuscript now carefully does not draw a link to drug safety; the title needs to do the same.As the paper is focused upon DPP-IV structure and function, more papers on this topic could be cited and linked with the data. For example, the author\'s amendment mentions contacts in DPP-IV at Glu205, Glu206 and Tyr662. The authors could state that Glu205 and Glu206 have been shown to be essential for catalysis by DPP-IV and cite the paper [Abbott *et al.* (1999)](http://www.ncbi.nlm.nih.gov/pubmed/10570924).

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Chakraborty

Sandeep

Tata Institute of Fundamental Research, India

**Competing interests:**No competing interests were disclosed.
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We would like to thank you for your positive comments, and your informative suggestions.

We agree with your suggested change in the title. In the latest version, we have also cited the research you have brought to our attention.
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The successful targeting of DPP4 using small molecule compounds to treat type 2 diabetes has attracted a great deal of attention towards the study of this protease.

The authors applied sophisticated techniques that they have developed in order to discover that two DPP4 inhibitors, including one that is in limited clinical use, can to some extent inhibit the activity of a bacterial lipase (PI-PLC). Many lipases and esterases and hydrolases including DPP4 and related enzymes use the *alpha/beta* hydrolase fold and the authors show how this related protein topology can place the residues in positions that are sufficiently similar to interact with an inhibitor. 

The major difficulty with this paper is that it attempts to connect these data with possible clinical outcomes. No evidence for such a link is presented. Therefore, the title and much of the conclusions need to be modified so that they reflect the data without speculation.

Two inhibitors of DPP4, LAF237 and K-579, were studied. K-579 is not in clinical use. LAF237 is licensed in Europe and is known to exhibit some inhibition of the DPP4-related proteases DPP8 and DPP9. The extent of inhibition of DPP8 and DPP9 by LAF237 is believed not to have physiological effects in humans. The IC50 of LAF237 on DPP9 is less than 0.01 mM. The IC50 of LAF237 on bacterial PI-PLC is 0.1mM, which is close to the lower limit of detection of inhibition of an enzyme. No mammalian homolog of PI-PLC was examined.

The literature that the authors cite to suggest that DPP4 inhibition might be detrimental for human health, particularly the pancreas, is data on sitagliptin or exenatide. Exenatide is not a DPP4 inhibitor and sitagliptin is quite different to LAF237, both in protease specificity and in chemical structure. The contact points of LAF237 and sitagliptin in the catalytic site of DPP4 differ considerably. The authors present no data on sitagliptin or any other DPP4 inhibitor (other than LAF237) that in is the clinic.

The images of overlaid catalytic triads of various enzymes presented in Fig 1 and Fig 3 need to be depicted in 3D in order to evaluate how close they are in 3D. Intermolecular distances should be shown on thee figures. To convince the reader that LAF237 sits into and makes contacts with enzymes other than DPP4, we need to see the compound docked into the structure of each enzyme of interest.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Chakraborty

Sandeep

Tata Institute of Fundamental Research, India

**Competing interests:**No competing interests were disclosed.
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We would like to thank you for taking the time to review this paper, and also for your insightful comments. We also apologize for the inordinate time taken to respond to your comments. A lot of this time was spent in understanding docking methods, instead of blindly applying this to the problem at hand. A by-product of this learning process was the implementation of a new method (DOCLASP) for docking molecules to proteins ^1^. We have docked vildagliptin to the PI-PLC structure complexed with myo-inositol using DOCLASP. Based on your suggestion, we have also

done a comprehensive analysis of all 76 known DPP4 structures liganded to inhibitors till date.

Please find out detailed responses to your comments below. *The successful targeting of DPP4 using small molecule compounds to treat type 2 diabetes has attracted a great deal of attention towards the study of this protease. The authors applied sophisticated techniques that they have developed in order to discover that two DPP4 inhibitors, including one that is in limited clinical use, can to some extent inhibit the activity of a bacterial lipase (PI-PLC). Many lipases and esterases and hydrolases including DPP4 and related enzymes use the alpha/beta hydrolase fold and the authors show how this related protein topology can place the residues in positions that are sufficiently similar to interact with an inhibitor. The major difficulty with this paper is that it attempts to connect these data with possible clinical outcomes. No evidence for such a link is presented. Therefore, the title and much of the conclusions need to be modified so that they reflect the data without speculation.*We have tried to keep away from taking sides on the clinical outcomes, since that is not our forte. Also, we believe our title is innocuous in that context - it just speaks of promiscuous scaffolds. We only highlight that if (and only if) our data of PIPLC inhibition holds true for human lipases, then it might provide some arguing points for those worried about the side effects of these drugs.For example, we say 'The reported elevated levels of serum lipase, although contested, could be rationalized by inhibition of lipases reported here'. If you could kindly point out specifically any speculations that is unwarranted, we will modify those.*Two inhibitors of DPP4, LAF237 and K-579, were studied. K-579 is not in clinical use. LAF237 is licensed in Europe and is known to exhibit some inhibition of the DPP4-related proteases DPP8 and DPP9. The extent of inhibition of DPP8 and DPP9 by LAF237 is believed not to have physiological effects in humans.*Since this study does not emphasize on the clinical relevance of the inhibitions (but on the methodology of finding such interactions), and we are not a group specializing in diabetes, we believe the choice of the inhibitors would not alter our reasoning our conclusions.*The IC50 of LAF237 on DPP9 is less than 0.01 mM. The IC50 of LAF237 on bacterial PI-PLC is 0.1mM, which is close to the lower limit of detection of inhibition of an enzyme.*We agree to this point. However, K-579 was inhibiting even at nanomolar concentrations.*No mammalian homolog of PI-PLC was examined.*We are currently evaluating that possibility.*The literature that the authors cite to suggest that DPP4 inhibition might be detrimental for human health, particularly the pancreas, is data on sitagliptin or exenatide. Exenatide is not a DPP4 inhibitor and sitagliptin is quite different to LAF237, both in protease specificity and in chemical structure.*We were referring to the inhibitor part of the data, but that point needs to be made explicit as you have correctly pointed out. Also, we agree that the possible difference of sitagliptin with LAF237 needs to be stated. We have modified the text to include these criticisms. Once again, we reiterate we intend not to comment on clinical outcomes or debates, but to suggest a rational methodology to act as a guide for tests that look for possible interactions.*The contact points of LAF237 and sitagliptin in the catalytic site of DPP4 differ considerably. The authors present no data on sitagliptin or any other DPP4 inhibitor (other than LAF237) that in is the clinic.*We have included a comprehensive study on the contact points of various inhibitors. Once again, this does not negate any of our conclusions.*The images of overlaid catalytic triads of various enzymes presented in Fig 1 and Fig 3 need to be depicted in 3D in order to evaluate how close they are in 3D.*The 3D images of the superimposition of these enzymes are not pleasing to the eye, since they lack structural homology. However, we have added a PyMol script in case someone wishes to do that (Superimposeproteins.p1m). The script specifies the color coding of the residues.*Intermolecular distances should be shown on thee figures.*Once again, we think that the intermolecular distances clutter the figure. The superimposition gives an approximate idea of the congruence. The exact values are specified in Table 1. We have modified the legend of Fig.3 to specify that.*To convince the reader that LAF237 sits into and makes contacts with enzymes other than DPP4, we need to see the compound docked into the structure of each enzyme of interest.*As mentioned previously, we have docked sitagliptin to PI-PLC using DOCLASP ^1^. We have provided the Pymol script as supplementary data to help visualize the docking. There is no solved structure where LAF237 inhibits DPP4.

Once again, we are thankful for the comments. We hope that we have addressed your concerns by the changes that we have made, and that the manuscript will be found suitable in the modified form.

**References** Chakraborty S. *DOCLASP* - Docking ligands to target proteins using spatial and electrostatic congruence extracted from a known holoenzyme and applying simple geometrical transformations \[v2; ref status: awaiting peer review, <http://f1000r.es/4pb>\] *F1000Research* 2014, **3**:262 (doi: [10.12688/f1000research.5145.2](http://dx.doi.org/10.12688/f1000research.5145.2))
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**Disclaimer: I lack the protein chemistry expertise to comment on the assumptions and protein chemistry used in the computational method described in this article.**

The title and abstract are appropriate.The overall experimental design is simple but strong and well suited for this project. The methods were generally well described. The conclusions are not overstated and any implications are justified based on the presented data. The article is very well written.   

This is a very interesting study that uses a previously defined computational method, CataLytic Active Site Prediction (CLASP), that compares structural and charge similarities of catalytic sites to identify functionally similar proteins. This methodology was used to assess the potential for adverse events based on off target effects of the inhibitors of DPP-IV. Using CLASP, the authors had previously indentified a Bacillus cerus phosphoinositide specific phospholipase-C (PI-PLC) as similar in active catalytic site to the enzyme, DPP-IV. They used laboratory techniques to verify this finding. 

In the present study, the authors demonstrated the ability of two separate DPP-IV inhibitors to significantly reduce the activity of this PI-PLC in the lab. Subsequent to this experimentation, the authors returned CLASP to identify catalytic sites in other proteins that might also be inhibited by DPP-IV inhibitors thereby yielding unforeseen inhibition and biological effects. As applied to the case of DPP-IV inhibitors, which are not extremely specific, the authors identify a number of other proteins that could be promiscuously impacted by DPP-IV inhibitors thereby providing mechanisms for unexpected adverse events. Although the significance of DPP-IV inhibitor related adverse events has yet to be determined, the fact that changes have been reported non-clinically and clinically are undeniable. Eventually, the benefit of these molecules may far outweigh their associated risks, but the authors provide a potential path forward for investigation of unexpected events with this class of drug. If contradictory reports persist, this path may require further illumination. 

The approach is theoretically similar to using structural similarities to identify off target receptor binding and consequent biological effects, an expanding approach in safety assessment and in identification of mechanisms for adverse events in the pharmaceutical lifecycle. Similarly, this method could be predictive for off target effects and suggest what those effects might be. However, whether this is a method that can be generally applicable to other molecules is beyond my ability to comment and the scope of this work.

 Comments/Suggestions:

1) Were the inhibition experiments done in duplicate, triplicate, etc?  Some slight expansion of the protocols would help with attempts to replicate.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Rendón-Ramirez

Adela

Unidad de Biofisica CSIC UPV, Spain
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Dear Dr Rouse,

We would like to thank you for taking the time and reviewing our paper. Your positive comments encourage us to further our research in this area.

We concur with your statement - *\"Eventually, the benefit of these molecules may far outweigh their associated risks\"*. And it is our endeavor to improve the accuracy and generality of our method through different compounds. We would specifically like to highlight another case of antagonist binding identified through CLASP, although in this case most alkaline phosphatases were not affected - [Chakraborty *et al.*(2012)](http://www.sciencedirect.com/science/article/pii/S0014579312006874)

The data for PI-PLC inhibition using DPP4 inhibitors, as shown in Figure 2, are average values of two closely similar experiments. We will revise the manuscript to include this point when we hear from another referee.

Best regards,

Sandeep Chakraborty and Adela Rendón-Ramirez

[^1]: \*Equal contributors

[^2]: SC, ARR and BA performed the experiments. All authors analyzed the data, and contributed equally to the writing and subsequent refinement of the manuscript.

[^3]: **Competing interests:**No competing interests were disclosed.
